Level C· Early human research exploring benefitsProspective StudyEurope PMC

Nano Fat Therapy and Platelet Rich Plasma Versus Nano Fat Therapy Alone on Burn Scar

Bano N., Ali H., Pervez Khan M., Rizvi B., Zulfiqar B., Awan A.

Prospective Study on Chronic Wound, Burns, Scar, published in Ann Burns Fire Disasters (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Ann Burns Fire Disasters (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40589711
PMCID
PMC12186185

Abstract (original English)

The aim of the study was to identify the efficacy of platelet rich plasma plus nano fat therapy in comparison to nano fat therapy alone on burn scars. The study was conducted at the Department of Plastic & Reconstructive Surgery Dr. Ruth KM Pfau, Civil Hospital Karachi, Dow University of Health Sciences Pakistan from March 2021 to February 2022. Sixty-four patients with mature burn scar of both genders aged eighteen and above were included and randomly distributed in 2 groups: one group received treatment with nano fat therapy whereas the other group received treatment with nano fat therapy and platelet rich plasma. Vancouver scar scale (VSS) score was used to assess the scar at baseline, 1 month, 3 months and finally after 6 months. For both groups, the highest mean total VSS score values were observed at baseline and lowest at 6 months. All mean values at various points for the PRP + nano fat group were lower than mean values for the nano fat group. However, the mean difference between the two groups for scores after 6 months was insignificant. It was concluded that results of both treatments are equivocal.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research